Naleen Raj Bhandari, MS, PhD

Eli Lilly and Company, Indianapolis, IN, USA

Poster(s):

• 1524 - Patient-Reported Outcomes (PRO) among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) receiving Pirtobrutinib: Final Analysis from the BRUIN Phase 1/2 Study